Evidence map›Paper›PMID 26021191›Full record

ReviewGastroenterology clinics of North America2015

Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma.

Thomas M Runge, Julian A Abrams, Nicholas J Shaheen

3 registry-linked trialsOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gastroenterology clinics of North America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 101 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 7 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03813381 nacompletednot on this map

The Impact of a Moderate CAlorie and Protein REstriction PROgram (CARE-PRO) as an Efficient and Affordable Therapeutic Strategy in Patients With Barrett's Esophagus.

TypeinterventionalSponsorIstituto Oncologico Veneto IRCCSRan2015 to 2021Enrolled160ConditionsBarrett's Esophagus, Overweight and ObesityArmsCalorie and protein restriction diet
NCT05056051 naunknown statusnot on this mapstarted 2020, after this paper: background citation

Additive Value of Wide-Area Transepithelial Sampling (WATS3D) in Detection of Recurrence of Intestinal Metaplasia Following Endoscopic Eradication Therapy (EET) for Barrett's Esophagus-Related Neoplasia

TypeinterventionalSponsorNorthwestern UniversityRan2020 to 2025Enrolled200ConditionsBarrett Esophagus, Esophageal CancerArmsWATS-3D tissue sampling prior to forceps biopsies, WATS-3D tissue sampling following forceps biopsies
NCT05299476 phase2completednot on this mapstarted 2022, after this paper: background citation

A Single-arm, Open Phase II Trial of CAPOX Combined With Bevacizumab Combined With Tislelizumab in First-line Treatment of PDL1 CPS < 5 Locally Advanced or Metastati Gastroesophageal Adenocarcinoma

TypeinterventionalSponsorChinese PLA General HospitalRan2022 to 2025Enrolled32ConditionsAdvanced Gastroesophageal Adenocarcinoma, First-line Therapy, PDL1 CPS < 5ArmsCAPOX combined with bevacizumab and Tislelizumab
3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 7 syntheses or guidelines pooled it, 250 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline on screening for esophageal adenocarcinoma in patients with chronic gastroesophageal reflux disease.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2020
    Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Randomized Controlled Trial of the Gastrin/CCKCancer prevention research (Philadelphia, Pa.) · 2021
    Trial
  9. Article
  10. Article
  11. High Rates of Dysplasia in a Population-Based Analysis of "Incidental" Barrett's Esophagus.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026
    Article
  12. Current Concepts for Diagnosing Non-Dysplastic and Dysplastic Barrett's Esophagus.Gastrointestinal endoscopy clinics of North America · 2026
    Review
  13. Review
  14. Article
  15. Article
  16. The potential utility of CHATGPT4.0 as an AI assistant in the education and management of patients with Barrett's esophagus.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2025
    Article
  17. Article
  18. Review
  19. Article
  20. Observational

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Thomas M RungeDivision of Gastroenterology and Hepatology, Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, University of North Carolina at Chapel Hill, CB#7080, Chapel Hill, NC 27599-7080, USA.
Julian A AbramsDivision of Digestive and Liver Diseases, Columbia University Medical Center, 622 West 168th Street, PH 7W-318D, New York, NY 10032, USA.
Nicholas J ShaheenDivision of Gastroenterology and Hepatology, Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, University of North Carolina at Chapel Hill, CB#7080, Chapel Hill, NC 27599-7080, USA. Electronic address: nshaheen@med.unc.edu.
University of North Carolina at Chapel Hill · US

Funding

DIGESTIVE DISEASES EPIDEMIOLOGY TRAINING PROGRAMT32DK007634 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1990 to 2026
$7.4M
Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative TherapyK24DK100548 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SHAHEEN, NICHOLAS J · 2013 to 2017
$896k
NIDDK NIH HHS K24 DK100548NIDDK NIH HHS K24DK100548NIDDK NIH HHS T32 DK007634NIDDK NIH HHS T32 DK07634
6 · The paper itself

Abstract

Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC), a disease with increasing burden in the Western world, especially in white men. Risk factors for BE include obesity, tobacco smoking, and gastroesophageal reflux disease (GERD). EAC is the most common form of esophageal cancer in the United States. Risk factors include GERD, tobacco smoking, and obesity, whereas nonsteroidal antiinflammatory drugs and statins may be protective. Factors predicting progression from nondysplastic BE to EAC include dysplastic changes on esophageal histology and length of the involved BE segment. Biomarkers have shown promise, but none are approved for clinical use.

Indexed as

Helicobacter pyloriAdenocarcinomaAge FactorsAlcohol DrinkingBarrett EsophagusBiomarkersEsophageal NeoplasmsGastroesophageal RefluxHelicobacter InfectionsHumansIncidenceObesityPrecancerous ConditionsPrevalenceRisk FactorsSex FactorsBiomarkersBarrett’s esophagusEpitheliumEsophageal adenocarcinomaGastroesophageal reflux disease

Identifiers

PMID26021191
PMCPMC4449458
OpenAlexW2103246760

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.